Gastric Cancer Vaccine

A Novel Approach for Protecting Against Gastric Cancer and Helicobacter pylori-associated Disease

The opportunity
Helicobacter pylori infect the stomachs of half the world’s population. The worldwide prevalence of this infection means that large numbers of people suffer from H. pylori-associated diseases, including peptic ulcers and gastric adenocarcinoma (hereafter gastric cancer).

Gastric cancer is the 3rd leading cause of death due to cancer globally, with approximately 734,000 gastric cancers annually attributable to H. pylori. It is well established that gastric cancers develop as a direct result of severe chronic inflammation (gastritis) in response to infection with H. pylori. Indeed, along with the human papillomavirus and the hepatitis B and C viruses, H. pylori is a leading cause of cancer due to infection (see Figure 1).

Sales of the human papillomavirus vaccine Gardasil (Merck) totalled US$2.03 billion in 2014 and are forecast to reach US$2.52 billion by 2020. In 2013, sales of GSK’s Hepatitis vaccine franchise totalled US$984 million.

In the US, the direct costs associated with peptic ulcer disease (a high proportion of which would be associated with H. pylori infection) are approximately $2.6 billion annually. Further, health economics studies have shown a vaccine against H. pylori in the US would be cost effective.

H. pylori infections are currently treated with combination of antibiotics; however, there are several reasons why antibiotics can not be used in the prevention of gastric cancer, including:

- Rising H. pylori antibiotic resistance.
- The majority of people are asymptomatic for H. pylori infection before being diagnosed with gastric cancer, i.e. no point for intervention unless screening is undertaken.
- Screening and population level antibiotic use is likely to increase the prevalence of antibiotic-resistant pathogens within the community.

Accordingly, there is a clinical need and commercial and economic rationale for a vaccine against H. pylori, especially to protect against gastric cancers.

To date, efforts to make a vaccine against H. pylori have largely failed because of the ability of H. pylori to evade host protective immunity. Researchers at MCRI, led by Associate Professor Phil Sutton, have developed a novel vaccine strategy that, rather than eradicating infection, prevents the H. pylori-induced inflammation that is responsible for disease.

The technology
The vaccine candidate is recombinant HtrA, a ~55 kDa protein and the only serine protease produced by H. pylori. HtrA is both expressed on the bacterial surface and secreted, and is essential for H. pylori survival.

Researchers at MCRI have shown that mice vaccinated with HtrA are protected against H. pylori-induced gastritis compared to controls (Figure 2).

![Fig 1](image1.png)

**Figure 1** World cancer incidence attributable to infections in 2008 (data from Lancet Oncology, Vol. 13, Issue 5, 2012).

![Fig 2](image2.png)

**Figure 2** Therapeutic vaccination protects against H. pylori-induced gastritis.

![Average H. pylori infected control mouse](image3.png)

Average H. pylori infected control mouse

![Average therapeutically vaccinated mouse](image4.png)

Average therapeutically vaccinated mouse
**Proposed mechanism of action:** *H. pylori* HtrA has been shown to disrupt the epithelial barrier by cleaving E-cadherin, thereby opening the junctions between gastric epithelial cells. It is proposed that a leaky epithelium allows shed bacterial components, and possibly a limited number of whole bacteria, to cross the epithelial barrier into underlying tissues, interacting with cells of the immune system and driving gastritis (Figure 3).

In support of the proposed mechanism of action, MCRI researchers have shown that sera from HtrA-vaccinated mice neutralises HtrA protease activity in vitro (Figure 4).

**Applications**
In addition to a therapeutic or prophylactic vaccine against *H. pylori*-induced disease.

**Opportunity for partnership**
The Murdoch Children’s Research Institute is seeking a partner to develop the gastric cancer vaccine technology through either a research development and option agreement or license agreement.

**Intellectual Property**
This technology is the subject of a series pending National Phase patent applications (Europe, China, Japan, USA, Russia, South Korea, Australia, Brazil) in the name of the Murdoch Children’s Research Institute. The application relates to methods of treating or preventing bacteria induced inflammation and immunogenic compositions comprising a HtrA polypeptide or a fragment.

**Key publications**

**Contact:**
Dr Joanne Boag
Head of IP & Licensing – Biotech & Medtech
P +613  8341 6445
joanne.boag@mcri.edu.au